Menu Open
▽
△
Menu Close

> > > 【スタッフ紹介】松岡 賢市

【スタッフ紹介】松岡 賢市

【卒業年】　1999年（平成11年）

【学位取得年月】2006年（平成18年）3月

【専門領域】　血液内科学，造血幹細胞移植学

【資格】
認定内科医（日本内科学会），血液専門医・指導医（日本血液学会），造血細胞移植認定医（日本造血細胞移植学会）

【略歴】
1999年　　岡山大学医学部卒業
1999年　　亀田総合病院 臨床研修医
2001年　　亀田総合病院 血液・腫瘍内科 医員
2002年　　岡山大学病院 血液・腫瘍内科 医員
2003年　　岡山大学大学院医歯薬学総合研究科博士課程（2006年修了）
2006年　　岡山大学病院 血液・腫瘍内科 助手
2006年　　ハーバード大学ダナファーバーがん研究所 研究員（Jerome Ritz研）
2010年　　ハーバード大学医学部 Instructor of Medicine
2011年　　岡山大学病院 血液・腫瘍内科 助教
2014年　　岡山大学 血液・腫瘍・呼吸器・アレルギー内科学　外来医長
2016年　　岡山大学 血液・腫瘍・呼吸器・アレルギー内科学　医局長
2016年　　岡山大学病院 血液・腫瘍内科 講師
2018年　　岡山大学大学院 血液・腫瘍・呼吸器内科学 准教授

【賞罰】
平成18年度 岡山医学賞
平成25年度 日本血液学会奨励賞

【一言】
お一人おひとりに合った丁寧な診療を心がけています。
安全な移植医療を提供できるよう、真に患者さんのもとへ届く臨床と研究を続けたいと願っています。

【研究テーマ】
・ＧＶＨＤとＧＶＬ：基礎メカニズムの解明
・臨床移植における効果的な免疫モニタリング系の確立
・制御性T細胞を活用する新規免疫制御療法の臨床開発

【主な業績】

Sumii Y, Kondo T, Ikegawa S, Fukumi T, Iwamoto M, Nishimura MF, Sugiura H, Sando Y, Nakamura M, Meguri Y, Matsushita T, Tanimine N, Kimura M, Asada N, Ennishi D, Maeda Y, Matsuoka KI.
Hematopoietic stem cell-derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide.
JCI Insight. 2023 Apr 24;8(8):e162180.

Terao T, Matsuoka KI, Ueda H, Matsumura A, Matsubara C, Kondo K, Kondo T, Fujiwara H, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Maeda Y.
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML.
Blood Advances. 2023 Mar 14;7(5):681-686.

Meguri Y, Asano T, Yoshioka T, Iwamoto M, Ikegawa S, Sugiura H, Kishi Y, Nakamura M, Sando Y, Kondo T, Sumii Y, Maeda Y, Matsuoka KI.
Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
Front Immunol. 2022 Aug 2;13:891925.

Sugiura H, Matsuoka KI, Fukumi T, Sumii Y, Kondo T, Ikegawa S, Meguri Y, Iwamoto M, Sando Y, Nakamura M, Toji T, Ishii Y, Maeda Y.
Donor Treg expansion by liposomal α-galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graft-versus-host disease.
Immun Inflamm Dis. 2021 Sep;9(3):721-733.

Ikegawa S, Matsuoka KI.
Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives.
Front Immunol. 2021 Aug 30;12:713358.

Nakamura M, Meguri Y, Ikegawa S, Kondo T, Sumii Y, Fukumi T, Iwamoto M, Sando Y, Sugiura H, Asada N, Ennishi D, Tomida S, Fukuda-Kawaguchi E, Ishii Y, Maeda Y, Matsuoka KI.
Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression.
Sci Rep. 2021 Jun 23;11(1):13125.

Kondo T, Ikegawa S, Fukumi T, Sumii Y, Sugiura H, Sando Y, Nakamura M, Meguri Y, Iwamoto M, Maeda Y, Matsuoka KI.
Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells.
Immunohorizons. 2021 Jun 10;5(6):424-437.

Terao T, Matsuoka KI, Narita K, Tsushima T, Yuyama S, Kuzume A, Tabata R, Miura D, Takeuchi M, Matsue K.
Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide.
Front Oncol. 2021 Apr 29;11:666774.

Ikegawa S, Meguri Y, Mizuhara K, Fukumi T, Kobayashi H, Sumii Y, Kondo T, Sando Y, Iwamoto M, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Fujisawa Y, Imai T, Maeda Y, Matsuoka KI.
Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab.
Leukemia. 2021 Mar;35(3):929-931

Iwamoto M, Ikegawa S, Kondo T, Meguri Y, Nakamura M, Sando Y, Sugiura H, Sumii Y, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Shibakura M, Maeda Y, Matsuoka KI.
Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease.
Bone Marrow Transplant. 2021 Apr;56(4):956-959.

Sando Y, Matsuoka KI, Sumii Y, Kondo T, Ikegawa S, Sugiura H, Nakamura M, Iwamoto M, Meguri Y, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Utsunomiya A, Oka T, Maeda Y.
5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy.
Sci Rep. 2020 Oct 14;10(1):17237.

Ikegawa S, Meguri Y, Kondo T, Sugiura H, Sando Y, Nakamura M, Iwamoto M, Maeda Y, Matsuoka KI.
PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade.
Blood Advances. 2019 Dec 10;3(23):4081-4094.

Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.
Matsuoka KI.
Int J Hematol. 2018 Feb;107(2):130-137.

Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Maeda Y, Tanimoto M, Ritz J, Matsuoka KI.
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Blood. 2017 Apr 13;129(15):2186-2197.

Ishikawa T, Fujii N, Imada M, Aoe M, Meguri Y, Inomata T, Nakashima H, Fujii K, Yoshida S, Nishimori H, Matsuoka KI, Kondo E, Maeda Y, Tanimoto M.
Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Cytotherapy. 2017 Apr;19(4):514-520.

Asano T, Matsuoka KI, Iyama S, Ohashi K, Inamoto Y, Ohwada C, Murata M, Satake A, Yoshida C, Nakase K, Mori Y, Tanimoto M.
Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease.
Acta Med Okayama. 2016 Oct;70(5):429-433.

Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, Otsuka E, Henzan H, Kato K, Tomoyose T, Yamamoto H, Kurosawa S, Matsuoka K, Yamaguchi T, Fukuda T.
Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
J Clin Oncol. 2016 Oct 1;34(28):3426-33.

Fujiwara H, Maeda Y, Sando Y, Nakamura M, Tani K, Ishikawa T, Nishimori H, Matsuoka K, Fujii N, Kondo E, Tanimoto M.
Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin.
Transfusion. 2016 Apr;56(4):886-92.

Nishie M, Fujii N, Mimura Y, Asano T, Mimura-Kimura Y, Aoe K, Aoe M, Nakashima H, Fujiwara H, Nishimori H, Matsuoka K, Kondo E, Maeda Y, Tanimoto M.
Vigorous inflammatory responses in noninfectious pulmonary complication induced by donor lymphocyte infusion.
Transfusion. 2016 Jan;56(1):231-6.

Okamoto S, Fujiwara H, Nishimori H, Matsuoka K, Fujii N, Kondo E, Tanaka T, Yoshimura A, Tanimoto M, Maeda Y.
Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-γ/IL-17-producing cells.
J Immunol. 2015 Feb 1;194(3):1357-63.

Fujiwara H, Maeda Y, Kobayashi K, Nishimori H, Matsuoka K, Fujii N, Kondo E, Tanaka T, Chen L, Azuma M, Yagita H, Tanimoto M.
Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
J Immunol. 2014 Sep 1;193(5):2565-73.

Murase K, Kim HT, Bascug OR, Kawano Y, Ryan J, Matsuoka K, Davids MS, Koreth J, Ho VT, Cutler C, Armand P, Alyea EP, Blazar BR, Antin JH, Soiffer RJ, Letai A, Ritz J.
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.
Haematologica. 2014 Sep;99(9):1499-508.

Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, Ritz J.
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
Science Translational Medicine. 2013; 5(179):179ra43.

Low-Dose Interleukin-2 for Regulatory T-cell Enhancement in Chronic GVHD.
Koreth J, Matsuoka K, Kim HT, McDonough S, Bindra B, Alyea EP, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Soiffer RJ, Ritz J.
New England Journal of Medicine, 2011;365:2055-66.

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, Soiffer RJ, Ritz J.
Journal of Clinical Investigation. 2010 May;120(5):1479-93

Sugiyama H, Maeda Y, Nishimori H, Yamasuji Y, Matsuoka K, Fjii N, Kondo E,
Shinagawa K, Takeuchi K, Teshima T, and Tanimoto M.
mTOR inhibitors permit regulatory T cell reconstitution and inhibit chronic GVHD.
Biol Blood Marrow Transplant. 2013

Kawano Y, Kim HT, Matsuoka K, Bascug G, McDonough S, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J.
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation
Blood. 2011 ;118(18):5021-30.

Koyama M, Hashimoto D, Aoyama K, Matsuoka K, Karube K, Niiro H, Harada M, Tanimoto M, Akashi K, Teshima T.
Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells.
Blood. 2009 26;113(9):2088-95　

Aoyama K, Koyama M, Matsuoka K, Hashimoto D, Ichinohe T, Harada M, Akashi K, Tanimoto M, Teshima T.
Improved outcome of allogeneic bone marrow transplantation due to breast-feeding-induced tolerance to maternal antigens.
Blood. 2009; 113(8):1829-33,　

Teshima T, Wynn TA, Soiffer RJ, Matsuoka K-I, Martin PJ.
Chronic graft-versus-host disease: how can we release Prometheus?
Biology of Blood and Marrow Transplantation 2008; 01.

Matsuoka K, Ichinohe T, Hashimoto D, Asakura S, Tanimoto M, Teshima T.
Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+ CD25+ T-cell-dependent mechanism.
Blood 2006; 107:404.

Ichinohe T, Teshima T, Matsuoka K, Maruya E, Saji H.
Fetal-maternal microchimerism: impact on hematopoietic stem cell transplantation.
Current Opinion in Immunology 2005;17: 546.

戻る